Amicus Therapeutics Completes Merger with BioMarin Subsidiary, Deregisters Securities

summarizeSummary

Amicus Therapeutics, Inc. has completed its merger with Lynx Merger Sub 1, Inc., a wholly-owned subsidiary of BioMarin Pharmaceutical Inc., and has subsequently deregistered all unsold securities from its previous S-3 registration statements.

check_boxKey Events

• Merger Completion

  Amicus Therapeutics has officially merged with Lynx Merger Sub 1, Inc., a wholly-owned subsidiary of BioMarin Pharmaceutical Inc., effective April 27, 2026.

• Company Status Change

  As a result of the merger, Amicus Therapeutics is now a wholly-owned subsidiary of BioMarin Pharmaceutical Inc., ceasing to be an independent public entity.

• Securities Deregistration

  All previously registered but unsold securities under various S-3 registration statements have been removed from registration, as offerings have terminated due to the merger.

auto_awesomeAnalysis

This filing confirms the definitive completion of the merger between Amicus Therapeutics and Lynx Merger Sub 1, Inc., a wholly-owned subsidiary of BioMarin Pharmaceutical Inc. As a result, Amicus Therapeutics is no longer an independent publicly traded company. This event marks the final step in the acquisition process, following the recent French regulatory clearance announced on April 23, 2026. The deregistration of securities is a procedural consequence of the merger's completion, signifying the termination of all prior offerings and sales of Amicus's securities.